For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Loteprednol Etabonate Base (QD) | Loteprednol etabonate ophthalmic base dosed once/day. | None | None | 0 | 21 | 0 | 21 | View |
| Loteprednol Etabonate Base (BID) | Loteprednol etabonate ophthalmic base dosed two times/day | None | None | 0 | 20 | 4 | 20 | View |
| Loteprednol Etabonate Base (QID) | Loteprednol etabonate ophthalmic base dosed four times/day. | None | None | 0 | 20 | 5 | 20 | View |
| Loteprednol Etabonate Suspension (QID) | Loteprednol etabonate ophthalmic suspension dosed four times/day | None | None | 0 | 20 | 1 | 20 | View |
| Vehicle of Loteprednol Etabonate | Vehicle of loteprednol etabonate, dosed either QD, BID, or QID | None | None | 0 | 20 | 6 | 20 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Eye irritation | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (12.1) | View |
| Eye pruritis | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (12.1) | View |
| Blurred vision | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (12.1) | View |
| Neck pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | MedDRA (12.1) | View |
| Oropharyngial pain | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA (12.1) | View |
| Eye pain | SYSTEMATIC_ASSESSMENT | Eye disorders | MedDRA (12.1) | View |
| Back pain | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | MedDRA (12.1) | View |
| Myalgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | MedDRA (12.1) | View |
| Temporomandibular joint syndrome | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | MedDRA (12.1) | View |
| Post nasal drip | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | MedDRA (12.1) | View |
| Muscle strain | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | MedDRA (12.1) | View |
| Road traffic accident | SYSTEMATIC_ASSESSMENT | Injury, poisoning and procedural complications | MedDRA (12.1) | View |
| Ear pain | SYSTEMATIC_ASSESSMENT | Ear and labyrinth disorders | MedDRA (12.1) | View |
| Blood oestrogen decreased | SYSTEMATIC_ASSESSMENT | Investigations | MedDRA (12.1) | View |
| Dysgeusia | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA (12.1) | View |